Breakthrough in Relapsed Multiple Myeloma With PANORAMA 1 Study

Speaking to European Medical Journal from the 19th Congress of the European Hematology Association (EHA) 2014 meeting, Prof Paul ┬áRichardson, Dana-Farber Cancer Institute, Boston, Masschusetts, USA, discusses results seen from the ‘breakthrough’ PANORAMA 1 study, a global randomised, double-blind, placebo-controlled Phase III study of panobinostat in combination with bortezomib and dexamethasone in patients with relapsed multiple myeloma. ┬áProf Richardson outlines the primary end-point results and side-effects observed, and comments on the clinical meaningfulness of these results. ┬áResults of sub-sets of higher risk groups are also discussed, and Prof Richardson comments on new data with ricolinostat (ACY-1215) in multiple myeloma.

Year of Production:
Running Time:


Comments are closed.